Open Nav

Terry Hermiston

CEO

GLAdiator Biosciences, Inc

Dr. Hermiston has over 20 years of R&D experience in the life science industry, having held senior positions at Bayer Healthcare, Berlex Biosciences and Onyx Pharmaceuticals. In these roles he has been responsible for assembling and managing teams of scientists and research associates, most recently as the head of Bayer HealthCare’s R&D site located in Mission Bay in San Francisco. While at Bayer Dr. Hermiston co-chaired the Early Research portfolio in Hematology and the Early Research portfolio in Immuno-Oncology and Antibody Drug Conjugates. While at Onyx, he was responsible for the oncolytic virus research program and at Berlex invented the oncolytic virus, Enadenotucirev, that is currently in Phase II clinical trials in partnership with BMS. Dr. Hermiston recently completed the acquisition of the novel PS targeting technology from Bayer and formed GLAdiator Biosciences to pursue its applications in oncology.

This speaker's sessions:

Back